These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

413 related articles for article (PubMed ID: 34341132)

  • 21. STING agonist delivery by tumour-penetrating PEG-lipid nanodiscs primes robust anticancer immunity.
    Dane EL; Belessiotis-Richards A; Backlund C; Wang J; Hidaka K; Milling LE; Bhagchandani S; Melo MB; Wu S; Li N; Donahue N; Ni K; Ma L; Okaniwa M; Stevens MM; Alexander-Katz A; Irvine DJ
    Nat Mater; 2022 Jun; 21(6):710-720. PubMed ID: 35606429
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combination cancer immunotherapy targeting TNFR2 and PD-1/PD-L1 signaling reduces immunosuppressive effects in the microenvironment of pancreatic tumors.
    Zhang X; Lao M; Xu J; Duan Y; Yang H; Li M; Ying H; He L; Sun K; Guo C; Chen W; Jiang H; Zhang X; Bai X; Liang T
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35260434
    [TBL] [Abstract][Full Text] [Related]  

  • 23. STING-Activating Small Molecular Therapeutics for Cancer Immunotherapy.
    Huang C; Tong T; Ren L; Wang H
    Chembiochem; 2024 Oct; 25(19):e202400255. PubMed ID: 38980259
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cancer immunotherapy based on image-guided STING activation by nucleotide nanocomplex-decorated ultrasound microbubbles.
    Li X; Khorsandi S; Wang Y; Santelli J; Huntoon K; Nguyen N; Yang M; Lee D; Lu Y; Gao R; Kim BYS; de Gracia Lux C; Mattrey RF; Jiang W; Lux J
    Nat Nanotechnol; 2022 Aug; 17(8):891-899. PubMed ID: 35637356
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Design, Synthesis, and Biochemical and Biological Evaluation of Novel 7-Deazapurine Cyclic Dinucleotide Analogues as STING Receptor Agonists.
    Vavřina Z; Perlíková P; Milisavljević N; Chevrier F; Smola M; Smith J; Dejmek M; Havlíček V; Buděšínský M; Liboska R; Vaneková L; Brynda J; Boura E; Řezáčová P; Hocek M; Birkuš G
    J Med Chem; 2022 Oct; 65(20):14082-14103. PubMed ID: 36201304
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combination of PD-1 Inhibitor and OX40 Agonist Induces Tumor Rejection and Immune Memory in Mouse Models of Pancreatic Cancer.
    Ma Y; Li J; Wang H; Chiu Y; Kingsley CV; Fry D; Delaney SN; Wei SC; Zhang J; Maitra A; Yee C
    Gastroenterology; 2020 Jul; 159(1):306-319.e12. PubMed ID: 32179091
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discovery of IACS-8803 and IACS-8779, potent agonists of stimulator of interferon genes (STING) with robust systemic antitumor efficacy.
    Ager CR; Zhang H; Wei Z; Jones P; Curran MA; Di Francesco ME
    Bioorg Med Chem Lett; 2019 Oct; 29(20):126640. PubMed ID: 31500996
    [TBL] [Abstract][Full Text] [Related]  

  • 28. STING, a promising target for small molecular immune modulator: A review.
    Liu Y; Lu X; Qin N; Qiao Y; Xing S; Liu W; Feng F; Liu Z; Sun H
    Eur J Med Chem; 2021 Feb; 211():113113. PubMed ID: 33360799
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hypoxia-activated prodrug and antiangiogenic therapies cooperatively treat pancreatic cancer but elicit immunosuppressive G-MDSC infiltration.
    Liu A; Gammon ST; Pisaneschi F; Boda A; Ager CR; Piwnica-Worms D; Hong DS; Curran MA
    JCI Insight; 2024 Jan; 9(1):. PubMed ID: 37988164
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Induction of tumor regression by intratumoral STING agonists combined with anti-programmed death-L1 blocking antibody in a preclinical squamous cell carcinoma model.
    Gadkaree SK; Fu J; Sen R; Korrer MJ; Allen C; Kim YJ
    Head Neck; 2017 Jun; 39(6):1086-1094. PubMed ID: 28323387
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inverse Correlation of STAT3 and MEK Signaling Mediates Resistance to RAS Pathway Inhibition in Pancreatic Cancer.
    Nagathihalli NS; Castellanos JA; Lamichhane P; Messaggio F; Shi C; Dai X; Rai P; Chen X; VanSaun MN; Merchant NB
    Cancer Res; 2018 Nov; 78(21):6235-6246. PubMed ID: 30154150
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The stimulator of interferon genes (STING) agonists for treating acute myeloid leukemia (AML): current knowledge and future outlook.
    Song X; Peng Y; Wang X; Chen Q; Lan X; Shi F
    Clin Transl Oncol; 2023 Jun; 25(6):1545-1553. PubMed ID: 36587109
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Discovery of BI 7446: A Potent Cyclic Dinucleotide STING Agonist with Broad-Spectrum Variant Activity for the Treatment of Cancer.
    Kuttruff CA; Fleck M; Carotta S; Arnhof H; Bretschneider T; Dahmann G; Gremel G; Grube A; Handschuh S; Heimann A; Hofmann MH; Impagnatiello MA; Nar H; Rast G; Schaaf O; Schmidt E; Oost T
    J Med Chem; 2023 Jul; 66(14):9376-9400. PubMed ID: 37450324
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biodegradable STING agonist nanoparticles for enhanced cancer immunotherapy.
    Wilson DR; Sen R; Sunshine JC; Pardoll DM; Green JJ; Kim YJ
    Nanomedicine; 2018 Feb; 14(2):237-246. PubMed ID: 29127039
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Activation of STING in the pancreatic tumor microenvironment: A novel therapeutic opportunity.
    Chamma H; Vila IK; Taffoni C; Turtoi A; Laguette N
    Cancer Lett; 2022 Jul; 538():215694. PubMed ID: 35489447
    [TBL] [Abstract][Full Text] [Related]  

  • 36. STING activation reprograms tumor vasculatures and synergizes with VEGFR2 blockade.
    Yang H; Lee WS; Kong SJ; Kim CG; Kim JH; Chang SK; Kim S; Kim G; Chon HJ; Kim C
    J Clin Invest; 2019 Jul; 129(10):4350-4364. PubMed ID: 31343989
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Engineered PLGA microparticles for long-term, pulsatile release of STING agonist for cancer immunotherapy.
    Lu X; Miao L; Gao W; Chen Z; McHugh KJ; Sun Y; Tochka Z; Tomasic S; Sadtler K; Hyacinthe A; Huang Y; Graf T; Hu Q; Sarmadi M; Langer R; Anderson DG; Jaklenec A
    Sci Transl Med; 2020 Aug; 12(556):. PubMed ID: 32801144
    [TBL] [Abstract][Full Text] [Related]  

  • 38. STING activation promotes robust immune response and NK cell-mediated tumor regression in glioblastoma models.
    Berger G; Knelson EH; Jimenez-Macias JL; Nowicki MO; Han S; Panagioti E; Lizotte PH; Adu-Berchie K; Stafford A; Dimitrakakis N; Zhou L; Chiocca EA; Mooney DJ; Barbie DA; Lawler SE
    Proc Natl Acad Sci U S A; 2022 Jul; 119(28):e2111003119. PubMed ID: 35787058
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Development of STING Agonists and Emerging Results as a Cancer Immunotherapy.
    Hines JB; Kacew AJ; Sweis RF
    Curr Oncol Rep; 2023 Mar; 25(3):189-199. PubMed ID: 36705879
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tumor-Derived Myeloid Cell Chemoattractants and T Cell Exclusion in Pancreatic Cancer.
    Vonderheide RH; Bear AS
    Front Immunol; 2020; 11():605619. PubMed ID: 33304355
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.